Xianzhu Biotechnology

Xianzhu Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, operating as a specialized research and development subsidiary of Simcere Pharmaceutical Group. The company focuses on the discovery and development of innovative oncology therapeutics, with a particular emphasis on next-generation immunotherapy and targeted biologics. Its pipeline includes a variety of modalities such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) targeting well-validated pathways like PD-L1/CTLA-4 and VEGF. Xianzhu leverages the extensive manufacturing and commercialization infrastructure of its parent company, Simcere, to accelerate the transition of its candidates from laboratory to clinic. The company's primary mission is to address unmet medical needs in the treatment of advanced solid tumors and hematological malignancies.